How can mpMRI change management of patients with NMIBC or MIBC?
María Natalia Gandur Quiroga, Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Ángel H. Roffo Oncology Institute in Buenos Aires, shared a post on X:
“How can mpMRI change management of patients with NMIBC or MIBC?
Presenter: Dirk Beyersdorff
Key Insights:-
- mpMRI: Superior to standard MRI/CT for staging bladder cancer.
- VI-RADS system: Standardizes mpMRI protocols for clinical & research use.
- Reduce invasiveness: Skip diagnostic cystoscopy in VI-RADS 1 & 2 cases.
Confirmatory biopsy (no deep TUR) for VI-RADS 5.
Challenges:-
Current TUR practices limit clinical relevance—pathways need reform.
Benefits:-
Better staging, fewer invasive procedures, and enhanced workflows!”
María Natalia Gandur Quiroga is a Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Ángel H. Roffo Oncology Institute in Buenos Aires, Argentina. She is a Professor of Medicine at the University of Buenos Aires at the Oncologists Post Graduates Studies. Her research focuses on clinical trials with aims to improve the treatment of patients with urologic tumors. She is an active member of the European Association for Cancer Research, Argentinian Medical Association and American Society of Clinical Oncology.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023